Kymera Therapeutics (KYMR) News Today $42.20 -1.10 (-2.54%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$41.93 -0.27 (-0.64%) As of 09/4/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Redmile Group LLC Lowers Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 4 at 7:28 AM | marketbeat.comKymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference TranscriptSeptember 3 at 2:03 PM | seekingalpha.comKymera Therapeutics appoints Adams as Chief Legal Officer, Corporate SecretarySeptember 3 at 12:05 PM | msn.comKymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate SecretarySeptember 3 at 7:00 AM | globenewswire.comInvesco Ltd. Has $1.15 Million Holdings in Kymera Therapeutics, Inc. $KYMRSeptember 3 at 3:38 AM | marketbeat.com122,605 Shares in Kymera Therapeutics, Inc. $KYMR Bought by Yiheng Capital Management L.P.September 1, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Shares Sold by Driehaus Capital Management LLCSeptember 1, 2025 | marketbeat.comNuveen LLC Purchases Shares of 143,238 Kymera Therapeutics, Inc. $KYMRAugust 30, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 60,000 Shares of Kymera Therapeutics, Inc. $KYMRAugust 28, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Shares Bought by Russell Investments Group Ltd.August 28, 2025 | marketbeat.comKymera Therapeutics to Participate in Upcoming September Investor ConferencesAugust 27, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Has $183.45 Million Position in Kymera Therapeutics, Inc. $KYMRAugust 27, 2025 | marketbeat.comDeutsche Bank AG Sells 18,435 Shares of Kymera Therapeutics, Inc. $KYMRAugust 25, 2025 | marketbeat.comKymera Therapeutics, Inc. $KYMR Stake Raised by Wellington Management Group LLPAugust 23, 2025 | marketbeat.comVanguard Group Inc. Raises Stake in Kymera Therapeutics, Inc. $KYMRAugust 23, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for KYMR FY2025 Earnings?August 17, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Downgraded by Wall Street Zen to SellAugust 17, 2025 | marketbeat.comAnalysts Are Updating Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Estimates After Its Second-Quarter ResultsAugust 16, 2025 | finance.yahoo.comB. Riley Lifts Earnings Estimates for Kymera TherapeuticsAugust 16, 2025 | marketbeat.comBrookline Capital Management Predicts KYMR Q3 EarningsAugust 16, 2025 | marketbeat.comLeerink Partnrs Analysts Raise Earnings Estimates for KYMRAugust 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for KYMR Q3 Earnings?August 15, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comKymera Therapeutics’ Earnings Call: Optimism and Strategic ProgressAugust 13, 2025 | msn.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down on Disappointing EarningsAugust 12, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Misses Expectations By $0.11 EPSAugust 12, 2025 | marketbeat.comKymera Therapeutics, Inc.: Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12, 2025 | finanznachrichten.deKymera Revenue Drops 55 Percent in Q2August 12, 2025 | theglobeandmail.comKymera Therapeutics Reports Q2 2025 Progress and PartnershipsAugust 11, 2025 | tipranks.comKymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 11, 2025 | globenewswire.comStocks With Rising Relative Price Strength: Kymera TherapeuticsAugust 6, 2025 | msn.comKymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | finance.yahoo.comTD Asset Management Inc Sells 26,468 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)August 3, 2025 | marketbeat.comVictory Capital Management Inc. Cuts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)August 3, 2025 | marketbeat.comQ2 Earnings Estimate for KYMR Issued By B. RileyAugust 2, 2025 | marketbeat.comB. Riley Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)July 31, 2025 | marketbeat.comKymera Therapeutics (KYMR) to Release Quarterly Earnings on WednesdayJuly 30, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 30, 2025 | marketbeat.comNeo Ivy Capital Management Invests $395,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 27, 2025 | marketbeat.comJennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)July 21, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs GroupJuly 18, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from AnalystsJuly 17, 2025 | marketbeat.comKymera Therapeutics Inc (KYMR) - Investing.comJuly 11, 2025 | investing.comQ3 EPS Estimate for Kymera Therapeutics Raised by AnalystJuly 9, 2025 | marketbeat.comKymera Therapeutics (KYMR) director group buys $13.9 million in stockJuly 3, 2025 | investing.comKymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan StanleyJuly 3, 2025 | marketbeat.comTuesday’s Insider Activity: Major Buys and Sells Shake Up MarketsJuly 3, 2025 | investing.comInsider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of StockJuly 2, 2025 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bvf Partners L. P/Il Purchases 317,167 SharesJuly 1, 2025 | marketbeat.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼1.330.70▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼86▲KYMR Articles Average Week Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies QGEN News Today BBIO News Today MRNA News Today VRNA News Today ELAN News Today ROIV News Today RVMD News Today GRFS News Today RYTM News Today LEGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.